Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bexarotene + Paclitaxel + Carboplatin in Advanced NSCLC
NCT00153842Phase 2Terminated
- Sponsor
- Dartmouth Health
- Start
- Aug 2001
- Primary completion
- Mar 2009
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label trial of bexarotene in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Dartmouth Health. Primary endpoints: Safety and Dose-Limiting Toxicities at 36 months and Objective Response Rate at 36 months. Started Aug 2001; status: terminated.
02
Drugs
bexarotene
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00153842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00153842.